Stock Events

Stock Events

Scynexis 

€4.84
57
-€0.20-3.97% Friday 19:33

Statistics

Day High
0.63
Day Low
0.6
52W High
0.996
52W Low
0.4865
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

17AugExpected
Q1 2026
Q2 2026
-2.85
-2.05
-1.24
-0.44
Expected EPS
-0.43986295605
Actual EPS
N/A

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap162.16B
Pfizer is a global pharmaceutical company that competes with Scynexis in the development of antifungal and antibacterial drugs.
Merck
MRK
Mkt Cap370.89B
Merck & Co., Inc. is involved in the development of anti-infective drugs, directly competing with Scynexis' focus on antifungal treatments.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences, Inc. offers antifungal and antiviral therapies, making it a competitor in the infectious disease market.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a portfolio that includes anti-infective drugs, competing with Scynexis in the pharmaceutical market.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments that compete with Scynexis' drug offerings.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie Inc. competes in the antifungal space with its own range of products, posing competition to Scynexis.
Novartis
NVS
Mkt Cap304.1B
Novartis AG engages in the development of drugs to treat a wide range of infections, including fungal, competing with Scynexis.
AMGEN
AMGN
Mkt Cap236.38B
Amgen Inc. has a diverse biopharmaceutical portfolio that includes treatments for infections, competing with Scynexis.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb has a range of anti-infective drugs, making it a competitor in the same market as Scynexis.
Sanofi
SNY
Mkt Cap106.01B
Sanofi operates in the pharmaceutical sector with a focus on anti-infectives among other areas, competing with Scynexis.

About

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Show more...
CEO
ISIN
US8112922005

Listings

STU
DE
135.STU
F
DE
135.F
MU
DE
135.MU
MU
DE
135A.MU

0 Comments

Share your thoughts

FAQ

What is Scynexis stock price today?▼
The current price of 135A.STU is €4.84 EUR — it has decreased by -3.97% in the past 24 hours. Watch Scynexis stock price performance more closely on the chart.
What is Scynexis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Scynexis stocks are traded under the ticker 135A.STU.
Is Scynexis stock price growing?▼
135A.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Scynexis has showed a -21.02% decrease.
In which sector is Scynexis located?▼
Scynexis operates in the Other sector.
When did Scynexis complete a stock split?▼
The last stock split for Scynexis was on June 01, 2026 with a ratio of 1:8.